Lifecore BiomedicalLFCR -3.78%55 Days Payable is 31.31 as of Mar. 2026, which is 50% below its 10-year median of 62.26. GuruFocus rates LFCR with a GF Score™ of 55/100 and a GF Value™ of $6.52 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 920 Drug Manufacturers companies, Lifecore Biomedical ranks worse than 80.11% on this metric.
The historical rank and industry rank for Lifecore Biomedical's Days Payable or its related term are showing as below:
LFCR'
s Days Payable Range Over the Past 10 Years
Min: 24.23 Med: 62.26 Max: 200.2
Current: 44.12
During the past 13 years, Lifecore Biomedical's highest Days Payable was 200.20. The lowest was 24.23. And the median was 62.26.
LFCR's Days Payable is ranked worse than 80.11% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs LFCR: 44.12
Lifecore Biomedical's Days Payable
declined
from Feb. 2025 (40.33) to Mar. 2026 (31.31).
It may suggest that Lifecore Biomedicalaccelerated paying its suppliers.
Lifecore Biomedical Days Payable Related Terms
Lifecore Biomedical Days Payable Historical Data
* Premium members only.
The historical data trend for Lifecore Biomedical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Days Payable distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Lifecore Biomedical's Days Payable for the fiscal year that ended in May. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecore Biomedical (LFCR) has a Days Payable of 31.31 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lifecore Biomedical and its competitors. This is 50% below median its historical median of 62.26. Over the past decade, Lifecore Biomedical's Days Payable has ranged from 24.23 to 200.20. According to the industry distribution chart, Lifecore Biomedical ranks #737 out of 920 companies in the Drug Manufacturers industry, placing it in the top 80.1%.
Is Lifecore Biomedical's Days Payable too high?
Lifecore Biomedical's current Days Payable of 31.31 is 50% below median its 10-year median of 62.26. Over the past 10 years, this metric has ranged from a low of 24.23 to a high of 200.20. The Drug Manufacturers industry median Days Payable is 90.84. Lifecore Biomedical's value of 31.31 is 65.5% below this industry median. Based on the distribution chart, Lifecore Biomedical ranks #737 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Days Payable compare to ANIK and DERM?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #737 out of 920 companies for Days Payable. This places Lifecore Biomedical in the lower half of its industry. The industry median Days Payable is 90.84. Lifecore Biomedical's value of 31.31 is 65.5% below this benchmark. Historically, Lifecore Biomedical's own Days Payable has ranged from 24.23 to 200.20 over the past decade. While the company's 10-year median is 62.26 vs. the industry median of 90.84, Lifecore Biomedical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lifecore Biomedical's current Days Payable of 31.31 is 65.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lifecore Biomedical and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current Days Payable is 31.31, which is 50% below median its own 10-year median of 62.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.52, compared to a current price of $4.97 — trading 23.8% below its estimated fair value. The current Days Payable is 31.31, which is 50% below median its 10-year median of 62.26 and 65.5% below the Drug Manufacturers industry median of 90.84. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Days Payable is 31.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (LFCR) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of $4.97 is trading 23.8% below its estimated GF Value™ of $6.52.
GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.
Key valuation signals for LFCR:
Days Payable: 31.31 (50% below median its 10-year median of 62.26)
GF Value™: $6.52 vs. price of $4.97 (23.8% below fair value)
Industry Position: 65.5% below the Drug Manufacturers median (#737 of 920)
No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score
Get the complete analysis for LFCR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFCR has been successfully added to your 
